Johnson & Johnson (JNJ)vsWarby Parker Inc (WRBY)
JNJ
Johnson & Johnson
$229.85
+1.10%
HEALTHCARE · Cap: $547.28B
WRBY
Warby Parker Inc
$22.53
-3.10%
HEALTHCARE · Cap: $2.63B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 10952% more annual revenue ($96.36B vs $871.90M). JNJ leads profitability with a 21.8% profit margin vs 0.2%. JNJ trades at a lower P/E of 26.3x. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
WRBY
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$229.85
$69.72 premium
Margin of Safety
+30.9%
Fair Value
$31.81
Current Price
$22.53
$9.28 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
No standout strengths identified
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
0.0% earnings growth
ROE of 0.5% — below average capital efficiency
0.2% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : WRBY
Revenue growth of 11.2% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : WRBY
The primary concerns for WRBY are EPS Growth, Return on Equity, Profit Margin. A P/E of 2147.0x leaves little room for execution misses. Thin 0.2% margins leave little buffer for downturns.
Key Dynamics to Monitor
JNJ profiles as a mature stock while WRBY is a value play — different risk/reward profiles.
WRBY carries more volatility with a beta of 2.08 — expect wider price swings.
WRBY is growing revenue faster at 11.2% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 34/100), backed by strong 21.8% margins. WRBY offers better value entry with a 30.9% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Warby Parker Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Warby Parker Inc. is a pioneering force in the direct-to-consumer eyewear sector, established in 2010 to transform the optical experience through a combination of online convenience and an expanding network of retail locations. The company emphasizes stylish, affordable prescription eyewear and sunglasses, uniquely positioning itself to attract a diverse customer base. Its socially responsible business model, highlighted by the "Buy a Pair, Give a Pair" initiative, underscores a commitment to community welfare, providing eyewear to those in need. With a strong brand identity and innovative marketing approaches, Warby Parker is poised for sustained growth and resilience in an increasingly competitive industry.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?